오믹스 기반 임상시험 시장 예측(2026-2032년)

The Omics-Based Clinical Trials Market is projected to grow by USD 64.32 billion at a CAGR of 8.94% by 2032.

Omics-based clinical trials are reshaping evidence generation by integrating genomics, transcriptomics, proteomics, metabolomics, epigenomics, microbiomics, and multi-omics analytics into drug development and precision medicine. These studies use molecular profiles to identify eligible participants, stratify responders, define biomarker-driven endpoints, monitor pharmacodynamic effects, and uncover mechanisms of disease progression or treatment resistance. The approach is increasingly relevant across oncology, rare diseases, immunology, neurology, cardiometabolic disorders, infectious diseases, and cell and gene therapy research, where conventional clinical variables alone may not capture biological heterogeneity. Regulatory agencies have issued frameworks for biomarker qualification, companion diagnostics, decentralized trial conduct, real-world evidence, and data integrity, supporting more structured adoption of omics in clinical research. At the same time, trial sponsors and research networks must manage challenges related to biospecimen quality, analytical validation, interoperability, privacy, cross-border data transfer, population diversity, and reproducibility. The executive priority is no longer whether omics will influence clinical trials, but how organizations can operationalize validated, ethical, and scalable omics workflows that improve patient selection, accelerate translational insight, and strengthen confidence in clinical decision-making.

Transformative Shifts in the Omics-Based Clinical Trials Landscape

The omics-based clinical trials landscape is undergoing a structural shift from broad-population trial designs toward biomarker-enriched, adaptive, and precision-guided protocols. Next-generation sequencing, high-throughput mass spectrometry, single-cell analysis, spatial biology, digital pathology, and advanced bioinformatics are enabling deeper biological characterization before, during, and after treatment. This shift is changing site selection, patient recruitment, protocol design, endpoint development, and post-trial evidence generation. Oncology has led adoption through genomic screening, molecular tumor boards, basket trials, umbrella trials, and minimal residual disease monitoring, while rare disease and immunology programs increasingly use multi-omics to identify disease subtypes and therapeutic targets. Decentralized and hybrid trials are also expanding access to sample collection and longitudinal monitoring, although they require standardized pre-analytical procedures and validated logistics for biospecimen transport. Another major transformation is the growing need for diverse reference datasets, as underrepresentation in genomic and biomarker databases can reduce the generalizability of trial findings. Industry leaders are therefore prioritizing harmonized data standards, federated analytics, consent modernization, and interoperable platforms that connect clinical, laboratory, imaging, wearable, and omics datasets into audit-ready evidence ecosystems.

Cumulative Impact of Artificial Intelligence on Omics-Based Clinical Trials

Artificial intelligence is amplifying the utility of omics-based clinical trials by improving signal detection across high-dimensional biological datasets. Machine learning models support biomarker discovery, molecular subtyping, patient matching, toxicity prediction, endpoint refinement, and identification of treatment-response patterns that may not be visible through conventional statistical methods. Natural language processing can assist with electronic health record screening and protocol feasibility, while knowledge graphs connect genes, pathways, variants, phenotypes, publications, and clinical outcomes. AI is also being used to improve quality control in sequencing and proteomics workflows, detect batch effects, support variant interpretation, and integrate multi-omics with histopathology and radiology. However, the cumulative impact of AI depends on explainability, prospective validation, bias assessment, and governance. Models trained on incomplete or demographically skewed datasets may underperform in diverse trial populations, and opaque algorithms can complicate regulatory review. For this reason, robust model documentation, traceable data provenance, clinically meaningful performance metrics, and human-in-the-loop oversight are becoming essential. The most durable value will come from combining AI with validated assays, clinically annotated datasets, privacy-preserving computation, and protocol designs that test algorithmic outputs in real-world trial settings.

Key Regional Insights for Omics-Based Clinical Trials

Asia-Pacific is becoming a critical region for omics-based clinical trials due to expanding sequencing capacity, large patient populations, government-backed precision medicine initiatives, and growing clinical research infrastructure across China, Japan, South Korea, India, Australia, and ASEAN economies. The region offers substantial opportunities for oncology, infectious disease, rare disease, and pharmacogenomics studies, while also requiring careful navigation of country-specific rules for genetic data, biospecimen export, and cybersecurity. North America remains a leading hub for biomarker-driven clinical research, supported by mature regulatory pathways for companion diagnostics, extensive academic medical networks, broad adoption of next-generation sequencing, and strong integration of real-world data into clinical development. Latin America is gaining relevance as sponsors seek more diverse enrollment and access to populations with underrepresented genomic ancestry, with Brazil and Mexico playing important roles in clinical research capacity, although infrastructure variability and ethics review timelines require proactive planning. Europe contributes strong scientific depth through cross-border research networks, biobanking systems, and data protection frameworks, with the European Health Data Space and in vitro diagnostic regulations influencing how omics evidence is generated and governed. The Middle East is investing in national genome programs, specialized medical cities, and precision medicine capabilities, particularly in Gulf economies where inherited disease research and population genomics are strategic priorities. Africa presents an essential opportunity to improve global representativeness in omics trials, as the continent holds the greatest human genetic diversity, yet requires continued investment in sequencing infrastructure, workforce training, bioinformatics capacity, ethical governance, and equitable benefit-sharing.

Key Group Insights for Omics-Based Clinical Trials

ASEAN is increasingly important for omics-based clinical trials as member states expand clinical research capabilities, digital health infrastructure, and genomic medicine programs, though regulatory harmonization, laboratory accreditation, and cross-border data governance remain uneven. GCC countries are advancing precision medicine through national genome initiatives, newborn and premarital screening programs, and investment in tertiary care research, making the region relevant for inherited disease, oncology, and population genomics studies. The European Union provides a highly structured environment for omics trials through coordinated research funding, strong data protection standards, clinical trial regulation, and evolving frameworks for in vitro diagnostics and health data sharing, which support high-quality evidence while increasing compliance complexity. BRICS countries collectively offer scale, disease diversity, and expanding scientific capability, with China and India contributing large recruitment potential, Brazil supporting Latin American representation, Russia maintaining established biomedical research capacity, and South Africa offering important genomic diversity and infectious disease expertise. G7 economies remain central to protocol innovation, regulatory science, companion diagnostic development, advanced bioinformatics, and global trial leadership due to mature healthcare systems and established research networks. NATO member countries overlap significantly with major clinical research markets in North America and Europe, and their relevance is strongest in data security, biosecurity, resilience of medical supply chains, and trusted research collaboration for sensitive genomic and health datasets.

Key Country Insights for Omics-Based Clinical Trials

The United States is a primary center for omics-based clinical trials due to extensive genomic testing adoption, biomarker-focused regulatory guidance, large academic research networks, and advanced biopharma trial infrastructure, while Canada contributes strong genomics research, population health data resources, and multicenter clinical trial expertise. Mexico is strengthening its role in North American and Latin American clinical research through growing trial site capacity and diverse patient access, while Brazil supports large-scale recruitment opportunities, oncology research, and population diversity critical for improving biomarker generalizability. The United Kingdom remains influential through national genomics programs, integrated health data assets, and strong translational medicine capabilities. Germany, France, Italy, and Spain provide high-quality clinical research environments, advanced laboratory networks, and active participation in European biomedical initiatives, while Germany is particularly strong in diagnostics and translational infrastructure, France in national health data and precision medicine programs, Italy in oncology and rare disease networks, and Spain in multicenter clinical trial execution. Russia maintains biomedical research capacity and specialist clinical centers, although international collaboration requires careful attention to geopolitical and regulatory constraints. China is advancing rapidly through large-scale genomics, oncology trial activity, digital health integration, and domestic precision medicine initiatives, but data localization and human genetic resource regulations require detailed compliance planning. India offers large patient populations, cost-efficient trial operations, expanding genomics capacity, and strong relevance for rare disease, oncology, infectious disease, and pharmacogenomics research. Japan combines regulatory maturity, aging-population research needs, oncology innovation, and pharmacogenomics expertise. Australia is recognized for efficient early-phase trial execution, strong ethics frameworks, and high-quality clinical infrastructure, while South Korea is a major precision medicine and oncology trial hub supported by advanced hospitals, high digital readiness, and sophisticated genomic research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should embed omics strategy at the earliest stages of clinical development rather than treating biomarker analysis as a retrospective add-on. Protocols should define the intended clinical use of each biomarker, assay validation requirements, biospecimen handling standards, statistical analysis plans, and decision rules for adaptive enrollment or stratification. Sponsors should prioritize diverse recruitment and community engagement to reduce genomic bias and improve external validity. Building interoperable data architectures that connect clinical outcomes, molecular profiles, imaging, pathology, wearable data, and real-world evidence will be essential for scalable insight generation. Organizations should also invest in qualified laboratories, standardized operating procedures, and chain-of-custody systems that preserve sample integrity across decentralized or multinational trials. AI tools should be deployed only with transparent validation, bias monitoring, and explainable outputs aligned with regulatory expectations. Privacy-preserving analytics, federated learning, dynamic consent, and secure cloud environments can support responsible cross-border collaboration. Finally, cross-functional governance involving clinical, regulatory, bioinformatics, laboratory, ethics, legal, and patient advocacy stakeholders should be established to ensure that omics-based trial designs are scientifically rigorous, operationally feasible, and aligned with patient benefit.

Research Methodology

This executive summary is based on secondary research and structured analysis of publicly available, verifiable sources, including regulatory guidance documents, clinical trial registries, peer-reviewed scientific literature, public health agency materials, standards organization publications, national genomics program information, ethics and data protection frameworks, and industry-relevant policy updates. The methodology emphasizes evidence triangulation across clinical, regulatory, technological, and geographic dimensions to assess how omics is being applied in clinical trial design and execution. Key themes were identified through analysis of biomarker-driven trial models, assay validation practices, multi-omics integration methods, AI applications, patient diversity considerations, regional governance requirements, and emerging data interoperability standards. No market sizing, forecasting, or competitive share calculations were used. Insights were synthesized to provide an executive-level view of operational priorities, regional dynamics, and strategic implications for organizations conducting or supporting omics-based clinical trials.

Conclusion

Omics-based clinical trials are becoming central to precision medicine because they connect molecular biology with clinical outcomes in ways that can improve patient selection, clarify mechanisms of response, and support more targeted therapeutic development. The field is advancing through validated assays, adaptive protocols, AI-enabled analytics, interoperable data platforms, and broader use of real-world and longitudinal evidence. Regional and country-level differences in infrastructure, regulation, population diversity, and data governance will shape where and how these trials are conducted. The next phase of progress will depend on rigorous validation, ethical data use, inclusive enrollment, and transparent analytics rather than technology adoption alone. Organizations that align scientific innovation with operational discipline and patient-centered governance will be best positioned to generate reliable, actionable evidence from omics-based clinical research.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Omics-Based Clinical Trials Market, by Clinical Trial Type

• 7.1. Introduction
• 7.2. Interventional
  • 7.2.1. Blinded
  • 7.2.2. Non Randomized
  • 7.2.3. Open Label
  • 7.2.4. Randomized Controlled
• 7.3. Observational
  • 7.3.1. Cohort
  • 7.3.2. Cross Sectional
  • 7.3.3. Prospective
  • 7.3.4. Retrospective

8. Omics-Based Clinical Trials Market, by Trial Phase

• 8.1. Introduction
• 8.2. Phase I
• 8.3. Phase II
• 8.4. Phase III
• 8.5. Phase IV

9. Omics-Based Clinical Trials Market, by Omics Type

• 9.1. Introduction
• 9.2. Genomics-Based Clinical Trials
• 9.3. Transcriptomics-Based Clinical Trials
• 9.4. Proteomics-Based Clinical Trials
• 9.5. Metabolomics-Based Clinical Trials
• 9.6. Multi-Omics Clinical Trials

10. Omics-Based Clinical Trials Market, by Application

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
  • 10.2.1. Arrhythmia
  • 10.2.2. Coronary Artery Disease
  • 10.2.3. Heart Failure
  • 10.2.4. Hypertension
• 10.3. CNS Disorders
  • 10.3.1. Alzheimer's Disease
  • 10.3.2. Epilepsy
  • 10.3.3. Multiple Sclerosis
  • 10.3.4. Parkinson's
• 10.4. Infectious Diseases
  • 10.4.1. Hepatitis
  • 10.4.2. HIV
  • 10.4.3. Influenza
  • 10.4.4. Tuberculosis
• 10.5. Inflammatory Diseases
  • 10.5.1. Crohn's Disease
  • 10.5.2. Psoriasis
  • 10.5.3. Rheumatoid Arthritis
  • 10.5.4. Ulcerative Colitis
• 10.6. Oncology
  • 10.6.1. Breast Cancer
  • 10.6.2. Colorectal Cancer
  • 10.6.3. Lung Cancer
  • 10.6.4. Prostate Cancer

11. Omics-Based Clinical Trials Market, by End User

• 11.1. Introduction
• 11.2. Academic & Research Institutes
• 11.3. Contract Research Organizations
• 11.4. Hospitals & Diagnostic Centers
• 11.5. Pharmaceutical & Biotech Companies

12. Omics-Based Clinical Trials Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Omics-Based Clinical Trials Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Omics-Based Clinical Trials Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 10x Genomics, Inc.
• 16.2. Agilent Technologies, Inc.
• 16.3. Bio-Rad Laboratories, Inc.
• 16.4. Bruker Corporation
• 16.5. Charles River Laboratories International, Inc.
• 16.6. Danaher Corporation
• 16.7. Eurofins Scientific SE
• 16.8. Guardant Health, Inc.
• 16.9. ICON Public Limited Company
• 16.10. Illumina, Inc.
• 16.11. IQVIA Holdings Inc.
• 16.12. Labcorp Holdings Inc.
• 16.13. Medpace Holdings, Inc.
• 16.14. Natera, Inc.
• 16.15. NeoGenomics, Inc.
• 16.16. Oxford Nanopore Technologies plc
• 16.17. Pacific Biosciences of California, Inc.
• 16.18. Personalis, Inc.
• 16.19. QIAGEN N.V.
• 16.20. Revvity, Inc.
• 16.21. SGS Societe Generale de Surveillance SA
• 16.22. Standard BioTools Inc.
• 16.23. Tempus AI, Inc.
• 16.24. Thermo Fisher Scientific Inc.
• 16.25. WuXi AppTec Co., Ltd.